<DOC>
	<DOCNO>NCT01595750</DOCNO>
	<brief_summary>REVASC randomize , double-blind , placebo-controlled study involve 150 patient chronic bronchitis COPD diagnose cardiovascular disease . The recruitment period beginimg coming week , last nine month . Patients include study receive treatment three month roflumilast 500 mg ( 75 patient ) placebo ( 75 patient ) randomize manner . The CIBERES , promoter study expect release final result third quarter 2013 . Eight center Madrid involve clinical trial : Fundación Jiménez Díaz , Hospital La Princesa , Hospital Gregorio Maranon Hospital Clinico San Carlos , Hospital La Paz , Hospital Ramón Cajal Hospital Doce de Octubre Hospital Puerta del Hierro . Roflumilast potent phosphodiesterase-4 inhibitor ( PDE4 ) . Its clinical efficacy study extensive clinical program involve 12,000 patient COPD . In study , roflumilast ( combination long-acting bronchodilator ) reduce number exacerbation improve lung function , especially patient associated chronic bronchitis .</brief_summary>
	<brief_title>Randomized , Double-blind , Placebo-controlled Study Evaluate Effect Roflumilast Endothelial Function Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Signed inform consent 5575 year age Current former smoker &gt; 20 cigarette packyr ( former smoker withdraw &gt; 1 year ) Diagnosis COPD ( GOLD criteria1 year V0 ) Presence chronic bronchitis ( cough and/or expectoration 3 months/yr 2 consecutive yr . absence potential cause ) Postbronchodilator FEV1 &lt; 70 % reference Presence establish CVD , CVD equivalent diabetes mellitus Presence chronic systemic inflammation , determine : 1 . Serum CRP ≥ 2 &lt; 10 mg/l 2 . Serum fibrinogen &gt; 518 mg/dl Leucocytes &gt; 8,6*106 /mm3 Episode COPD exacerbation and/or COPD treatment change last 2 month V0 History asthma , significant residual lung lesion bronchiectasis chest xray Apneahypopnea syndrome Poorly control CVD risk factor ( Table 2 ) and/or change treatment last 3 month V0 Clinically significant cardiac arrhythmia valve disease Severe concomitant immunological , inflammatory , infectious neoplastic disease Moderate severe hepatic insufficiency ( B C class , follow ChildPugh scale ) Severe neurologic and/or psychiatric disorder , include depression suicidal idea Alcohol and/or drug abuse last 12 month V0 Hypersensitivity roflumilast excipients Pregnancy potential pregnancy Participation clinical trial last 30 day V0 Language difficulty follow instruction study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Post-bronchodilator FEV1 &lt; 70 % reference</keyword>
	<keyword>Chronic bronchitis</keyword>
	<keyword>Presence estavlished CVD ,</keyword>
	<keyword>CVD equivalent diabetes mellitus</keyword>
</DOC>